Patents by Inventor Jan-Robert Schwark

Jan-Robert Schwark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090143473
    Abstract: Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for the production of a medicament for the normalization of serum lipids. The active compounds identified as inhibitors of the cellular Na+/H+ exchanger (NHE) are used for the production of a medicament for the normalization of serum lipids. They are used for the production of a medicament for lowering the blood lipid level and illnesses caused thereby, as well as the endothelial dysfunction syndrome and illness caused thereby.
    Type: Application
    Filed: February 3, 2009
    Publication date: June 4, 2009
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Hans Jochen LANG, Hans-Willi JANSEN, Jan-Robert SCHWARK, Heinz-Werner KLEEMANN, Oliver JUNG, Hans-Ludwig SCHAFER, Wolfgang LINZ, Werner KRAMER, Bernward SCHOLKENS, Eugen FALK
  • Patent number: 6825231
    Abstract: The application discloses substituted norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics and a medicament comprising them Substituted norbornylamino derivatives having exo-configured nitrogen and an endo-fused five-membered ring of the formula I, or having exo-configured nitrogen and an exo-fused five-membered ring of the formula I a in which R1, R2, R3, R4, R5, A, B, S1, and S2 are as defined in the claims, are highly suitable for use as antihypertensive agents, for reducing or preventing ischemically induced damage, for use as medicaments for surgical interventions for the treatment of ischemias of the nervous system, of stroke and cerebral edema, of shock, of impaired respiratory drive, for the treatment of snoring, as laxatives, as agents against ectoparasites, for the prevention of the formation of biliary calculus, as antiatherosclerotics, as agents against late diabetic complications, carcinomatous disorders, fibrotic disorders, endot
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: November 30, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Uwe Heinelt, Hans-Jochen Lang, Heinz-Werner Kleemann, Jan-Robert Schwark, Klaus Wirth, Hans-Willi Jansen
  • Publication number: 20040122096
    Abstract: Use of inhibitors of cellular Na+/H+ exchanger (NHE) for the production of a medicament for the normalization of serum lipids
    Type: Application
    Filed: October 8, 2003
    Publication date: June 24, 2004
    Applicant: Hoechst Aktiengesellschaft
    Inventors: Hans Jochen Lang, Hans-Willi Jansen, Jan-Robert Schwark, Heinz-Werner Kleemann, Oliver Jung, Hans-Ludwig Schafer, Wolfgang Linz, Werner Kramer, Bernward Scholkens, Eugen Falk
  • Publication number: 20040044081
    Abstract: Diacyl-substituted guanidines, a process for their preparation, their use as medicament or diagnostic aid, and medicament containing them.
    Type: Application
    Filed: August 15, 2003
    Publication date: March 4, 2004
    Applicant: Hoechst Aktiengesellschaft
    Inventors: Heinz-Werner Kleemann, Hans-Jochen Lang, Andreas Weichert, Peter Crause, Wolfgang Scholz, Udo Albus, Jan-Robert Schwark
  • Patent number: 6632840
    Abstract: Monoacyl-substituted guanidines of formula III, or a salt or acid thereof, and their use as medicine or diagnostic aid: in which X(2) is
    Type: Grant
    Filed: March 24, 2000
    Date of Patent: October 14, 2003
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Heinz-Werner Kleemann, Hans-Jochen Lang, Andreas Weichert, Peter Crause, Wolfgang Scholz, Udo Albus, Jan-Robert Schwark
  • Patent number: 6573288
    Abstract: The invention relates to compounds of formula (I) in which the symbols have the meanings given in the claims. Said compounds are inhibitors of the sodium-dependent bicarbonate/chloride ion exchanger which can be used as medicines for the prophylaxis or treatment of a wide range of diseases, for example the treatment and/or prophylaxis of myocardial infarction, angina pectoris, diseases caused by ischaemia, impaired respiration, cardiac ischaemia, ischaemia of the peripheral and central nervous system and stroke, ischaemia of the peripheral organs and limbs and diseases in which cell proliferation is a primary or secondary cause, in the treatment of shock, during surgical interventions and organ transplants or for preserving and storing transplants to be used in surgical interventions.
    Type: Grant
    Filed: November 3, 2000
    Date of Patent: June 3, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Andreas Weichert, Hans Jochen Lang, Stefan Petry, Jan-Robert Schwark, Heinz-Werner Kleemann, Sabine Faber, Hans-Willi Jansen
  • Patent number: 6504057
    Abstract: This invention relates to fluorophenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them. An embodiment of the invention embraces compounds of the formula I: and the pharmaceutically tolerated salts thereof. The disclosed compounds are valuable inhibitors of the cellular sodium/proton exchanger (Na+ /H+ exchanger) . They are therefore outstandingly suitable for the treatment of all diseases attributable to increased Na+ /H+ exchange.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: January 7, 2003
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Jan-Robert Schwark, Hans-Jochen Lang, Heinz-Werner Kleemann, Andreas Weichert, Wolfgang Scholz, Udo Albus
  • Patent number: 6486189
    Abstract: Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them. Compounds of the formula I in which the symbols have the meanings indicated in the claims, have outstanding antiarrhythmic properties and exhibit a cardioprotective component. They can preventively inhibit or greatly decrease the pathophysiological processes in the formation of ischemically induced damage, in particular in the elicitation of ischemically induced cardiac arrhythmias. Moreover, they have a potent inhibitory action on the proliferation of cells.
    Type: Grant
    Filed: October 30, 2001
    Date of Patent: November 26, 2002
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Heinz-Werner Kleemann, Hans Jochen Lang, Jan-Robert Schwark, Andreas Weichert, Sabine Faber, Hans-Willi Jansen
  • Publication number: 20020123529
    Abstract: This invention relates to fluorophenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them.
    Type: Application
    Filed: December 20, 2001
    Publication date: September 5, 2002
    Applicant: Hoechst Aktiengesellschaft
    Inventors: Jan-Robert Schwark, Hans-Jochen Lang, Heinz-Werner Kleemann, Andreas Weichert, Wolfgang Scholz, Udo Albus
  • Patent number: 6436999
    Abstract: Diacyl-substituted guanidines of the formula I are described where X(1) and X(2) are as defined herein. The compounds are suitable for use as antiarrhythmic pharmaceuticals possessing a cardioprotective component for the prophylaxis and treatment of infarction and for the treatment of angina pectoris, in connection with which they also inhibit or strongly reduce, in a preventitive manner the pathophysiological processes associated with the genesis of ischemically induced damage, in particular associated with the elicitation of ischemically induced cardiac arrhythmias.
    Type: Grant
    Filed: April 18, 1997
    Date of Patent: August 20, 2002
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Heinz-Werner Kleemann, Hans-Jochen Lang, Andreas Weichert, Peter Crause, Wolfgang Scholz, Udo Albus, Jan-Robert Schwark
  • Publication number: 20020045761
    Abstract: Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them.
    Type: Application
    Filed: October 30, 2001
    Publication date: April 18, 2002
    Inventors: Heinz-Werner Kleemann, Hans Jochen Lang, Jan-Robert Schwark, Andreas Weichert, Sabine Faber, Hans-Willi Jansen
  • Patent number: 6372917
    Abstract: The invention relates to compounds of formula (I), wherein the symbols have the meanings indicated in the specification. The inventive compounds exhibit dramatic antiarrhythmic proprieties and contain a cardioprotective compound. They can preventively inhibit or strongly reduce pathophysiologic processes upon occurrence of ischemic injuries, especially ischemic cardiac arrhythmia. Said compounds also exhibit a strong inhibiting effect on cellular proliferation.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: April 16, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Heinz-Werner Kleemann, Hans Jochen Lang, Jan-Robert Schwark, Andreas Weichert, Stefan Petry
  • Patent number: 6369236
    Abstract: The invention relates to compounds of formula (I), wherein the symbols have the meanings indicated in the specification. The inventive compounds exhibit dramatic antiarrhythmic proprieties and contain a cardioprotective compound. They can preventively inhibit or strongly reduce pathophysiologic processes upon occurrence of ischemic injuries, especially ischemic cardiac arrhythmia. Said compounds also exhibit a strong inhibiting effect on cellular proliferation.
    Type: Grant
    Filed: January 18, 2001
    Date of Patent: April 9, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Heinz-Werner Kleemann, Hans Jochen Lang, Jan-Robert Schwark, Stefan Petry, Andreas Weichert
  • Patent number: 6369069
    Abstract: The invention relates to compounds of the formula (I), in which the symbols have the following meaning: R(1) is 1. alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms; 2. alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, in which one to all hydrogen atoms are replaced by fluorine; 3. alkenyl having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms; or 4. —CnH2n−nn—Y, nn is zero or 2; and n is zero, 1, 2, 3 or 4; where n is unequal to zero or 1 if nn is equal to 2; 5. —CnH2n−nn—Y, nn is zero or 2; and n is 1, 2, 3 or 4; where n is unequal to 1 if nn is equal to 2.
    Type: Grant
    Filed: August 4, 2000
    Date of Patent: April 9, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Heinz-Werner Kleemann, Hans-Jochen Lang, Jan-Robert Schwark, Andreas Weichert, Sabine Faber, Hans-Willi Jansen, Stefan Petry
  • Patent number: 6335451
    Abstract: Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them. Compounds of the formula I in which the symbols have the meanings indicated in the claims, have outstanding antiarrhythmic properties and exhibit a cardioprotective component. They can preventively inhibit or greatly decrease the pathophysiological processes in the formation of ischemically induced damage, in particular in the elicitation of ischemically induced cardiac arrhythmias. Moreover, they have a potent inhibitory action on the proliferation of cells.
    Type: Grant
    Filed: January 21, 1998
    Date of Patent: January 1, 2002
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Heinz-Werner Kleemann, Hans Jochen Lang, Jan-Robert Schwark, Andreas Weichert, Sabine Faber, Hans-Willi Jansen
  • Publication number: 20010023257
    Abstract: The application discloses substituted norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics and a medicament comprising them
    Type: Application
    Filed: December 12, 2000
    Publication date: September 20, 2001
    Inventors: Uwe Heinelt, Hans-Jochen Lang, Heinz-Werner Kleemann, Jan-Robert Schwark, Klaus Wirth, Hans-Willi Jansen
  • Publication number: 20010020042
    Abstract: This invention relates to fluorophenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them.
    Type: Application
    Filed: February 8, 2001
    Publication date: September 6, 2001
    Applicant: Hoechst Aktiengesellschaft
    Inventors: Jan-Robert Schwark, Hans-Jochen Lang, Heinz-Werner Kleemann, Andreas Weichert, Wolfgang Scholz, Udo Albus
  • Patent number: 6262123
    Abstract: Ortho-substituted benzoylguanidines of the formula I in which R(1) to R(4) have the meanings given in the claims, are suitable, as antiarrhythmic pharmaceuticals having a cardioprotective component, for the prophylaxis and treatment of infarction and for the treatment of angina pectoris. They also inhibit, in a preventive manner, the pathophysiological processes associated with the genesis of ischemically induced damage, in particular associated with the triggering of ischemically induced cardiac arrhythmias.
    Type: Grant
    Filed: September 17, 1999
    Date of Patent: July 17, 2001
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Udo Albus, Joachim Brendel, Heinz-Werner Kleemann, Hans Jochen Lang, Wolfgang Scholz, Jan-Robert Schwark, Andreas Weichert
  • Patent number: 6166002
    Abstract: Substituted phenylalkenoylguanidines, processes for their preparation, uses as medicaments or diagnostics, and medicaments containing them are described.The invention relates to substituted phenylalkenoylguanidines and their pharmaceutically tolerable salts and physiologically functional derivatives of the formula ##STR1## in which the radicals have the meanings indicated, and their physiologically tolerable salts and processes for their preparation. The compounds are suitable as medicaments for the prophylaxis or treatment of gallstones.
    Type: Grant
    Filed: October 20, 1999
    Date of Patent: December 26, 2000
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Andreas Weichert, Alfons Enhsen, Eugene Falk, Hans-Willi Jansen, Werner Kramer, Jan-Robert Schwark, Hans Jochen Lang
  • Patent number: 6156800
    Abstract: There are described benzoylguanidines of the formula I ##STR1## where R(1) is R(4)--SO.sub.m, R(5)R(6)N--SO.sub.2 --; O.sub.p --(CH.sub.2).sub.q --(CF.sub.2).sub.r --CF.sub.3 ; --SR(10), --OR(10) or --CR(10)R(11)R(12); R(2) is --(CH.sub.2).sub.u --(CF.sub.2).sub.t --CF.sub.3 ; R(3) is hydrogen or independently defined as R(1); and their pharmaceutically tolerable salts. They are obtained by reaction of a compound of the formula II ##STR2## with guanidine. They are compounds of outstanding activity on the cardiovascular system.
    Type: Grant
    Filed: June 22, 1998
    Date of Patent: December 5, 2000
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Andreas Weichert, Joachim Brendel, Heinz-Werner Kleemann, Hans Jochen Lang, Jan-Robert Schwark, Wolfgang Scholz, Udo Albus